TB Online is no longer maintained. This is an archive of the site. For news on TB please go to: https://globaltbcab.org/

Twice-daily tenofovir alafenamide dose might overcome interaction with rifampicin

Twice-daily tenofovir alafenamide (TAF) plus rifampicin provided similar exposures to once-daily TAF in pharmacokinetic study. This strategy might be a suitable option for people with HIV/TB coinfection.

The results were presented at the 16th European AIDS Conference (EACS 2017), held on 25-27 October 2017 in Milan, Italy.

Read the full report by Polly Clayden, HIV i-Base here.

To subscribe to the Weekly Newsletter of new posts, enter your email here:


News

By Polly Clayden

Published: Oct. 31, 2017, 3:31 p.m.

Last updated: Oct. 31, 2017, 4:32 p.m.

Print Share